Inogen, Inc.

NASDAQ:INGN

Medical - Devices

Healthcare
$5.57 +0.71%

+$0.05 today

Market cap
$144.83M
Beta
1.59
P/E (TTM)
-7.0
EPS (TTM)
-$0.91
52W Low $5.34High $9.13

Volume 0.19M

Average 0.33M

INGN Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Inogen, Inc.NASDAQ: INGN

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $4.9M fell 5.5% year over year, behind the -2.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.6% from the prior quarter. Over 3 fiscal years it compounded at -4.2% a year.

Context

  • Depreciation & amortization amounted to 5.9% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -5.5% toward the trailing-twelve-month pace of -2.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.9M-2.6% QoQ
Last fiscal yearDec 2025
$20.66M-1.6% YoY
LTMMar 2026
$20.37M-2.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.5%——
1 year-1.6%——
3-year CAGR-4.2%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
20.66M USD
Year-over-year change
-1.6%
4-year CAGR
-1.1%

Depreciation & Amortization vs competitors

How INGN compares with its peers on the latest reported figures

  • INGN's LTM Mar 2026 depreciation & amortization of $20.37M is the 3rd largest of the 11 companies compared; the peer median is $3.19M.
  • Its year-over-year change of -2.6% is the 9th highest of 10, against a peer median of +35.4%.
  • Depreciation & amortization amounts to 5.8% of revenue for INGN, versus a peer median of 7.0%.
INGN Competitors Peer median
Depreciation & Amortization for INGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HCATHealth Catalyst, Inc.LTM Mar 2026$50.3M +18.5%+1.5%16.6%
QTRXQuanterix CorporationLTM Mar 2026$22.58M +148.0%+52.4%15.6%
INGNInogen, Inc.LTM Mar 2026$20.37M -2.6%-4.2%5.8%
NNOXNano-X Imaging Ltd.LTM Dec 2025$11.7M -0.3%+0.5%89.8%
SIShoulder Innovations, Inc.LTM Mar 2026$3.67M ——6.8%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$3.65M +35.4%+111.4%589.8%
OMOutset Medical, Inc.LTM Mar 2026$2.74M +63.9%-5.7%2.3%
SGHTSight Sciences, Inc.LTM Mar 2026$690K +3.1%-11.8%0.9%
HSDTSolana CompanyLTM Mar 2026$672K +1192.3%+30.5%7.0%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$263.36K +65.0%+17.8%—
SNWVSANUWAVE Health, Inc.LTM Mar 2026$103K -90.0%+10.5%0.2%
Peer median (excluding INGN) $3.19M+35.4%+10.5%7.0%

Competitors are the stored peer set for INGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(6.33M)(83.77M)(102.45M)(35.89M)(22.75M)
Depreciation & Amortization21.63M23.51M18.15M21M20.66M
Deferred Income Tax14.44M0(251K)(1.15M)(1.1M)
Stock-Based Compensation10.94M12.28M7.43M7.4M8.01M
Change in Working Capital(20.07M)(44.72M)14.27M(4.39M)(26.91M)
Accounts Receivables(5.42M)(51.62M)11.13M(5.07M)(14.62M)
Inventory(10.78M)(5.6M)7.88M(3.54M)(3.21M)
Accounts Payables(6.48M)6.76M(9.18M)(3.41M)5.6M
Other Working Capital2.61M5.74M4.44M7.63M(14.68M)
Other Non-Cash Items3.02M55.16M59.62M18.94M10.87M
Operating Cash Flow23.63M(37.53M)(3.23M)5.91M(11.22M)
Capital Expenditures(23.94M)(21.22M)(26.52M)(17.09M)(10.38M)
Acquisitions (Net)153K331K(29.44M)00
Purchases of Investments(9.99M)0(26.87M)(32.66M)(29.83M)
Sales of Investments19.26M10.01M24M35.5M14M
Other Investing Activities000(1.82M)0
Investing Cash Flow(14.65M)(10.88M)(59.32M)(13.98M)(26.21M)
Debt Repayment00000
Common Stock Issued15.65M1.74M1.48M811K28.18M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(647K)(1.36M)(518K)(546K)(4M)
Financing Cash Flow15M380K960K265K24.18M
Effect of Forex Changes(426K)(481K)67K(281K)846K
Net Change in Cash23.56M(48.51M)(61.52M)(8.08M)(12.4M)
Free Cash Flow(302K)(58.75M)(29.75M)(11.18M)(21.6M)

Inogen, Inc.

NASDAQ:INGN

Intrinsic Alpha fair value

Locked

Current Price

$5.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.